KarXT for Schizophrenia: Mechanism of Action?

Introducing KarXT: A New Paradigm
JAMA Psychiatry recently published (on May 1, 2024) the positive results of EMERGENT-3 trials for this potential non-dopaminergic medication for schizophrenia.
KarXT is a combination of two drugs: xanomeline and trospium chloride. This innovative therapy represents a significant departure from traditional antipsychotic treatments.
Read detailed post here: psychiatryeducationforum.com/...